The present findings in cancer patients are consistent with the saturability of platelet COX-1 inactivation at low aspirin doses with a three-quarter reduction in TXA2 biosynthesis with 100 mg aspirin daily and no further meaningful reduction observed with 300 mg daily [51, 54]. The gene discussed is PTGS1; the disease is cancer.